Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow MetaVia Inc.

Get SEC filing alerts via email and in your feed for MetaVia Inc.

MTVA

MetaVia Inc.

About MetaVia Inc.

MetaVia Inc. is a biotechnology company focused on developing pharmaceuticals for cardiometabolic diseases, including treatments for MASH and obesity. Its core programs include DA-1241, a GPR119 agonist for liver and diabetes, and DA-1726, a dual GLP-1 and glucagon receptor agonist for weight loss. The company advances its products through clinical trials, leveraging proprietary compounds, licensing agreements, and strategic collaborations in the biotech and pharmaceutical markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from MetaVia Inc.

1
1
MetaVia Inc. MetaVia Inc. Reports $3.8 Million Net Loss in Q1 2026, Highlights Clinical Advancements

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
MetaVia Inc. MetaVia Inc. Reports $13M Net Loss for Year Ended December 31, 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
MetaVia Inc. MetaVia Inc. Reports $3.4 Million Net Loss in Q3 2025, Significant Decrease in Operating Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
MetaVia Inc. MetaVia Inc. Reports Significant Reduction in Operating Expenses and Net Losses for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
MetaVia Inc. MetaVia Inc. Reports Improved Net Loss of $3.7 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
MetaVia Inc. NeuroBo Pharmaceuticals Reports $27.6 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
MetaVia Inc. NeuroBo Pharmaceuticals Reports Significant Changes in Revenue, Expenses, and Financial Health in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments